PATENT CLAIM ANALYSIS

Application Number: 16020457
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "635000"]

Abstract:
Provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production. In particular, provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production through administration of at least one of the following agents: 1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1; 2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and 3) an agent capable of inhibiting mitochondrial activity.

Claim (Index 13):
The method of  claim 12 ,\n wherein at least one of the one or more agents is an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1, wherein the agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1 is selected from Valspodar, Glyburide, Cyclosporine A, wherein at least one of the one or more agents is an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity, wherein the agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity is selected from the group consisting of Tariquidar, MK-571 (CAS 115103-85-0), Niguldipine hydrochloride (CAS 113317-61-6), Matairesinol (CAS 580-72-3), Reversin 121 (C 34 H 47 N 3 O 9 ), Elacridar (CAS 143664-11-3), Pyrimethamine (C 12 H 13 C1N 4 ), Pyrimethamine Biotin (C 27 H 39 N 7 O 3 S), Pyrimethamine-d3 (C 12 H 10 D 3 ClN 4 ), 8-isopentenylnaringenin (CAS 68682-02-0), JS-2190 (Boc-Glu(OBzl)-N,N\u2032-dicyclohexylurea, C 30 H 45 N 3 O 6 ), P-Glycoprotein Inhibitor C-4 (C 23 H 18 ClNO 4 ), PGP-4008 (CAS 365565-02-2), Sipholenol A (CAS 365565-02-2), Reversan (CAS 313397-13-6), CP 100356 hydrochloride (CAS 142716-85-6), PSC 833 (CAS121584-18-7), Zosuquidar trihydrochloride (CAS 167465-36-3), and Vismodegib (CAS 879085-55-9), wherein at least one of the one or more agents is an agent capable of inhibiting mitochondrial activity or ATP synthesis, wherein the agent capable of inhibiting mitochondrial activity or ATP synthesis is selected from the group consisting of rhodamine-123, MKT-077, decoquinate, isoniazid, suramin, erythrosine, toltrazuril, enilconazole, and metformin.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 94.0
- Lexical Diversity: 1.74074
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13802047', '15170682', '14798237', '14894281', '14148241']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.809416882228221
- 35 USC 102 Novelty (BERT): 0.5256821750371875
- Combined Prediction Score: 0.7810434115091176
- Mean Citation Score: 276.233942
- Max Citation Score: 313.12173
- Similarity Product: 167.74728733592391

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test